A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Phase 3
Completed
NCT05514535
| Condition | Diabetes Mellitus, Type 2, Obesity |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Novo Nordisk A/S |
|---|
| Status | Completed |
|---|
| Enrollment | 573 participants |
|---|
| Interventions | Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated) |
|---|
| Start date | Aug 29, 2022 |
|---|
| Completion date | Mar 5, 2025 |
|---|
| Results posted | May 11, 2026 |
|---|
Summary
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.
Change in Glycated Haemoglobin (HbA1c) [Noninferiority]
From baseline (week 0) to end of treatment (week 40) · Percentage point of HbA1c
| Insuline Glargine U100 (Reduced) + Semaglutide | -1.37 ± 0.84 Percentage point of HbA1c |
|---|
| Insuline Glargine U100 (Titrated) | -0.65 ± 0.92 Percentage point of HbA1c |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.